ABOUT US

Epygen Biotech Pvt Ltd (EBPL) would be launching its entry Biosimilar molecule Recombinant Streptokinase (rSK) in 2018, under License and Technology transfer by CSIR-IMTECH. This well-proven technology has been improvised for enhanced product performance and patient safety profile. Epygen’s oncology product pipeline consists Pegfilgrastim and Bevacizumab, jointly posting more than US$ 10 billion Global opportunity. It’s expertise on E.coli based expression of recombinant protein, coupled with innovative fermentation, protein refolding and separation techniques are utilized for high expression and purification of these molecules, making them affordable for patients in the region. The technology incubation center is based in Navi Mumbai and the plant is based in the heart of pharmaceutical production zone in Patalganga, near Mumbai.

ET NOW - FIRST TRADES

ET NOW - FIRST TRADES

Mr Debayan Ghosh Founder & President, Epygen Biotech

MANAGEMENT

Debayan Ghosh Co-Founder & President Epygen Labs

Debayan Ghosh

Co-Founder & President

Debayan’s vision for Epygen is to “emerge as a leading biotech innovator enhancing human life”. Having worked for leading Biotech companies in the United States and India for more than a decade prior to founding Epygen, Debayan realized the potential for biotechnology to shape tomorrow’s world, as in Epygen’s tag line “building future strand by strand”. Through his education and experience, he observed how modification of proteins using the recombinant path revolutionized areas from critical healthcare to chemicals and clean energy. Leading a team of scientists, technologists and business professionals at Epygen’s labs, manufacturing facilities and offices in Dubai, India and USA, innovation for sustainable development had been his key focus. Debayan obtained a Master of Technology degree from the Centre for Biotechnology – India, and has taken International business courses from the IIM. He has authored several scientific publications in international journals and patents.

Ariyarathenam Manickam Co-founder Epygen Labs

Ariyarathenam Manickam

Co-Founder

Ariyarathenam. M. is a self made Business man, who has, during his 30 years of experience, founded a multinational group of companies with 7 offices in 4 countries with total staff strength of more than 200. Ariyarathenam’s group companies are involved both in manufacturing and trading of speciality chemicals and also in the travel and tourism sector. Focussing his business mainly on the dynamic South Asian market with sourcing associations from USA, Europe and East Asian countries, Ariyarathenam is a well-travelled and updated businessman who changed the art of simple trading in his industry to best professional standards with full complement of qualified technical staff and laboratory support.

Ineeyan Ariyaratnam Director & Vice President Epygen Labs

Ineeyan Ariyaratnam

Director & Vice President

Before joining Epygen, Ineeyan worked as a Director of Business development & Finance with Fabpro Specialities, a Multinational specialty chemical corporation, where he restructured international sourcing and fund disbursement, developing new and profitable business verticals. Ineeyan has a BSc Business Management degree from Kings College of London and an MBA in Operations and Finance from SP Jain Institute.

SCIENTIFIC TEAM

Saptarshi Epygen Labs

Saptarshi Paul

Lead Scientist

Dr. Paul is an established scientist in the field of, Molecular biology and Biotechnology. Prior to joining Epygen he worked at the prestigious Tata Institute of Fundamental Research and US Vitamins for 13 years at various research levels on biosimilars and therapeutic protein development. For nearly a decade prior to that, Dr. Paul did research at Thomas Jefferson University-Philadelphia and UMDNJ-RWJMS, Rutgers, New Jersey, USA. His areas of expertise include recombinant therapeutics, mammalian and yeast gene cloning and expression, vector design and engineering, protein purification, gene regulation and protein engineering. Dr. Paul is a Ph.D. in Biochemistry from Jadavpur University, India.

Prabakaran Krishanmurthy Epygen Labs

Prabakaran K.

Chief Scientific Advisor

Dr. Prabakaran is a well known expert in the field of Protein Purification and Fermentation with more than two decades of experience in Fermentation and Downstream Purification of critical therapeutic proteins. With focus in the later stage of his career on chromatography of sensitive proteins, Dr. Prabakaran has led several bio-molecules to industrial success. Prior to Epygen Dr. Prabakaran served as Executive Vice President at Strides Acrolab and as Chief Scientific Officer at leading Bio-pharmaceutical companies in the region. He has done a post doctoral research at the prestigious AN Bach Institute of Biochemistry in Moscow and Ph.D. from Sardar Patel University, India.

Epygen Labs Punit

Punit Bansal

Senior Scientist

Dr. Punit is a specialist in preclinical Drug Discovery of metabolic disorders (diabetes and obesity), pain and inflammation. He has worked extensively over 8 years in pharmacological profiling of new drug molecules and his industrial experience prior to Epygen group had been with Panacea Biotec Ltd, India. He has several publications to his credit and reviews international journals. Punit holds a Ph. D. in Pharmacology from Manipal College of Pharmaceutical Sciences, India.

Rishikesh Epygen Labs

Rishikesh Gupta

Senior Scientist

Dr. Gupta is involved in Epygen as a Bioprocess Scientist developing fermentation technology, protein purification and strain development at the Biotech Incubation Center. Dr. Gupta has obtained his M.Tech. in Biotechnology and Ph.D. in Industrial Biotechnology from Anna University, Chennai, India.

Thangadurai Chinnathambi Epygen

Thangadurai C.

Senior Scientist

Dr. Thanga is a Genetic Engineer with several years of experience in cloning and expression of recombinant proteins from various origins. His Biotech Industry experience focuses on directed evolution of gene and high throughput robotic screening as well as designing of vectors to improve the over expressing proteins. Thanga conducted his Post Doctoral Research at the Dept. of Molecular Pharmacology /Therapeutics and Dept. of Physiology, at the Loyola University Medical Center, Maywood, Illinois, USA. He has a Ph.D. in Biotechnology from the Center for Biotechnology, Anna University, India.

CORPORATE CITIZENS

We believe in your success. Our efforts are to improve your life by innovation in biotechnology. Our science is aimed at exploration and discovery of new paths to a sustainable future.

We value the importance of our customers in using our revolutionary products and services. Our efforts are focused on understanding customer’s needs and anticipating how our science can be used to shape his future. Our success lies in his co-operation.

Our associates are our partners in advancement. We share the same goal and walk the extra mile for a better tomorrow.

As responsible corporate citizens, we pave ways to serve our society by utilizing our knowledge. We participate to improve education, social welfare and environment of the societies, we live and work.

We believe that our employees are our biggest asset and they will keep us ahead on the constantly emerging challenges in Biotechnology.

Epygen Biopharma Cardiovascular Image

CARDIOVASCULAR

Cardiovascular diseases (CVDs) have been leading cause of morbidity and mortality in India. During large-scale field trials: ISIS-3 (1992) Streptokinase (SK) has proven to be as efficacious in myocardial infarction as its more expensive counterparts e.g., tPA (Lancet, 1992).  Biosimilar Recombinant Streptokinase (rSK) was developed from in-vitro to animal and to clinical studies in patients with AMI. This rSK product expressed by a non-streptococcal bacterial organism has a dramatic effect on major disadvantageous features of the earlier version of SK, namely the induction of an antigenic response and of acute nonspecific febrile and hypotensive side effects.

PEGFILGRASTIM

Pegfilgrastim is a PEGylated form of recombinant human granulocyte colony stimulating factor (GCSF) an analog of Filgrastim. It helps in stimulating the level of WBCs (neutrophils) in patients with cancer (non-myeloid) who receive chemotherapy, that can cause fever and a low blood cell count (febrile neutropenia).

BEVACIZUMAB

Bevacizumab, a recombinant humanized monoclonal antibody developed against VEGF. It binds to soluble VEGF, preventing receptor binding and inhibiting endothelial cell proliferation and vessel formation. This reduces the tumor’s supply of oxygen and nutrients, therefore preventing its growth and survival. It is considered to be the first line treatment for metastatic colorectal cancer. It is also useful for other malignancy such as cervical cancer, glioblastoma, renal cell and non-squamous cancer, non-small cell lung cancer and metastatic breast cancer used as part of a combination chemotherapy regimen.

CONTACT US

    14-Raheja Arcade, Ground Floor CBD,
    Navi Mumbai, Maharashtra, India 400614

    +91 22 27560833

    info@epygen.com

     
    Copyright © 2016 Epygen Biotech Pvt Ltd. All Rights Reserved